ICH GCP R3 is now in English & EU languages. Book Now
  • Clinical Development
  • GCP & GxP Standards
  • Pharmacovigilance
  • Role Based
  • Distribution
  • Preclinical & Laboratory Foundations
  • Phase I – First-in-Human Trials
  • Phase II & III – Efficacy & Pivotal Trials
  • Clinical Trials Foundation PathNew

About

This Introduction to Good Pharmacovigilance Practice (GVP) is a concise, beginner-friendly foundation course covering what pharmacovigilance is, why drug safety matters and how the global regulatory landscape works. Across eight focused modules learners build core vocabulary (AE, ADR, SAE, SUSAR, signal, risk-benefit), walk the medicine lifecycle from pre-clinical to post-marketing, meet Individual Case Safety Reports, signal detection, risk management, and learn how to develop a Pharmacovigilance Plan aligned to ICH E2E, including FDA pharmacoepidemiologic assessment guidance and the four-section PV plan structure. The course closes with technology, AI and careers in PV — pointing learners toward Whitehall's advanced PV programmes for operational mastery.

Designed for PV new hires, nurses transitioning into pharma, pharmacists, life-science graduates, clinical research and regulatory staff, and corporate learners needing an annual GVP refresher. On completion you will define pharmacovigilance confidently, recognise EMA GVP / MHRA / FDA / ICH frameworks and EudraVigilance, apply core PV terminology correctly, place activities into the medicine lifecycle, describe ICSR fundamentals, walk the signal management lifecycle and risk minimisation toolkit, and plan progression into Whitehall's advanced PV courses. Aligned to EMA GVP Modules, MHRA expectations, FDA PV awareness, ICH E2 family and CIOMS conventions.

Course Syllabus

  1. What pharmacovigilance is
  2. How PV evolved
  3. The PV mission today
  4. Who does PV
  5. Pharmacovigilance and the wider system

  1. Why we need rules
  2. EMA GVP - the EU rule book
  3. MHRA, FDA and the rest of the world
  4. ICH and global harmonisation
  5. EudraVigilance and inspections

  1. AE, ADR and the family
  2. Expectedness, SUSAR and reporting
  3. Causality — who decides, and how
  4. Signals and risk-benefit

  1. The medicine lifecycle
  2. Approval and the handover
  3. Spontaneous reporting
  4. Literature and aggregate reporting
  5. Lifecycle thinking in practice

  1. What an ICSR is
  2. Inside a case
  3. Seriousness, expectedness, causality — applied
  4. Who reports — and by when
  5. How ICSRs fit the bigger picture

  1. What signal are
  2. How signals are detected
  3. Signal management lifecycle
  4. Risk minimisation and RMPs
  5. People and roles in signal management
  6. How to develop a Pharmacovigilance Plan
  7. Pharmacoepidemiologic assessment
  8. Contents of a Pharmacovigilance Plan

  1. Why technology matters in PV
  2. The tools you'll meet
  3. AI in pharmacovigilance
  4. Doing AI well in PV
  5. Human oversight — why it stays

  1. PV roles at a glance
  2. Where to start
  3. skills that build PV careers
  4. Specialist or generalist
  5. The Whitehall advanced PV programmes

Course Benefits

Benefits cpd_points icon
CPD Points

Gain Continuing Professional Development (CPD) Points, accredited by The Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. These can be used to count towards the distance learning element of any scheme that comes under the umbrella of The Academy of Medical Royal Colleges or any other scheme for which there is mutual recognition.

Benefits certification icon
Certification

Receive a personal certificate to show your subject knowledge on course completion.

Benefits affordable icon
Affordable

You get excellent value through our cost-effective prices. We can also offer you group discounts on larger purchases.

Benefits flexible icon
Flexibility

The course saves you time through the convenience of online availability. This lets you complete the interactive course at your own comfort.

Benefits up_to_date icon
Keep Up to Date

You will stay up to date with any changes to EMA GVP Modules, MHRA Pharmacovigilance guidance, FDA post-marketing requirements, ICH E2 safety guidelines and EudraVigilance reporting standards as this course is continuously monitored, reviewed and refreshed.

Benefits industry_experts icon
Learn from Industry Experts

The course content has been developed by Whitehall pharmacovigilance faculty drawing on EU, UK and US regulator practice and CIOMS conventions, so that learners build confident, inspection-ready foundations they can apply on the job from day one.


Our Certified Customers

novartis
NHS
takeda
roche
dhl

Learner Rating & Reviews

4.7
Average Rating
536 global ratings
87.0%
5.0%
3.0%
3.0%
2.0%
RC

Working with Whitehall training for the last two years of partnership has been a very successful experience – I have fast access to all the GCP course...

SM

I have finalised the demo for the ICH-GCP E6 R3 refresher course. Overall, I liked the content and the interface. I also want to thank Whitehall Train...